consensus statements on therapeutic drug monitoring of anti‐tumour necrosis factor therapy in inflammatory bowel diseases N Mitrev, N Vande Casteele, CH Seow, JM Andrews, SJ Connor, ... Alimentary pharmacology & therapeutics 46 (11-12), 1037-1053, 2017 | 280 | 2017 |
Pruritus ani SA Siddiqi, AM Siddika Keighley & Williams' Surgery of the Anus, Rectum and Colon, Fourth Edition …, 2018 | 93 | 2018 |
Therapeutic drug monitoring of biologics during induction to prevent primary non-response MP Sparrow, K Papamichael, MG Ward, P Riviere, D Laharie, S Paul, ... Journal of Crohn's and Colitis 14 (4), 542-556, 2020 | 76 | 2020 |
Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors MG Ward, B Warner, N Unsworth, SW Chuah, C Brownclarke, S Shieh, ... Alimentary Pharmacology & Therapeutics 46 (2), 150-161, 2017 | 71 | 2017 |
Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's Disease MG Ward, VC Kariyawasam, SB Mogan, KV Patel, M Pantelidou, ... Inflammatory bowel diseases 21 (12), 2839-2847, 2015 | 66 | 2015 |
determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease DJ Gibson, MG Ward, C Rentsch, AB Friedman, KM Taylor, MP Sparrow, ... Alimentary pharmacology & therapeutics 51 (6), 612-628, 2020 | 63 | 2020 |
Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions MG Ward, MP Sparrow, X Roblin Therapeutic advances in gastroenterology 11, 1756284818772786, 2018 | 58 | 2018 |
Intra‐patient variability in adalimumab drug levels within and between cycles in Crohn's disease MG Ward, PA Thwaites, L Beswick, J Hogg, G Rosella, ... Alimentary Pharmacology & Therapeutics 45 (8), 1135-1145, 2017 | 49 | 2017 |
IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti … N Mitrev, N Vande Casteele, CH Seow, JM Andrews, SJ Connor, ... Aliment Pharmacol Ther 46 (11-12), 1037-1053, 2017 | 49 | 2017 |
Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure E Flanagan, PR Gibson, EK Wright, GT Moore, MP Sparrow, W Connell, ... Alimentary Pharmacology & Therapeutics 52 (10), 1551-1562, 2020 | 45 | 2020 |
Thioguanine in inflammatory bowel disease: long-term efficacy and safety MG Ward, KV Patel, VC Kariyawasam, R Goel, B Warner, TR Elliott, ... United European Gastroenterology Journal 5 (4), 563-570, 2017 | 36 | 2017 |
Evaluation of the utility of the Vigileo FloTrac™, LiDCO™, USCOM and CardioQ™ to detect hypovolaemia in conscious volunteers: a proof of concept study E O'Loughlin, M Ward, A Crossley, R Hughes, AP Bremner, T Corcoran Anaesthesia 70 (2), 142-149, 2015 | 31 | 2015 |
Thiopurines dosed to a therapeutic 6-thioguanine level in combination with adalimumab are more effective than subtherapeutic thiopurine-based combination therapy or adalimumab … VC Kariyawasam, MG Ward, PA Blaker, KV Patel, R Goel, JD Sanderson, ... Inflammatory Bowel Diseases 23 (9), 1555-1565, 2017 | 28 | 2017 |
Is there a role for thioguanine therapy in IBD in 2017 and beyond? KM Taylor, MG Ward, PA Blaker, MP Sparrow Expert Review of Gastroenterology & Hepatology 11 (5), 473-486, 2017 | 22 | 2017 |
Therapeutic drug monitoring of subcutaneous infliximab in inflammatory bowel disease—understanding pharmacokinetics and exposure response relationships in a new era of … RD Little, MG Ward, E Wright, AJ Jois, A Boussioutas, GL Hold, ... Journal of Clinical Medicine 11 (20), 6173, 2022 | 19 | 2022 |
Practical management of inflammatory bowel disease patients during the COVID‐19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel … AA Aysha, C Rentsch, R Prentice, D Johnson, RV Bryant, MG Ward, ... Internal Medicine Journal 50 (7), 798-804, 2020 | 19 | 2020 |
A virtual clinic increases anti‐TNF dose intensification success via a treat‐to‐target approach compared with standard outpatient care in Crohn’s disease A Srinivasan, DR van Langenberg, RD Little, MP Sparrow, P De Cruz, ... Alimentary pharmacology & therapeutics 51 (12), 1342-1352, 2020 | 17 | 2020 |
The potential value of faecal lactoferrin as a screening test in hospitalized patients with diarrhoea DR Van Langenberg, RB Gearry, HL Wong, M Ward, PR Gibson Internal medicine journal 40 (12), 819-827, 2010 | 16 | 2010 |
Circulating tumour cell enumeration does not correlate with Miller–Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy SA O’Toole, C Spillane, Y Huang, MC Fitzgerald, B Ffrench, B Mohamed, ... Breast Cancer Research and Treatment 181, 571-580, 2020 | 15 | 2020 |
Effects of fiber intake on intestinal pH, transit, and predicted oral mesalamine delivery in patients with ulcerative colitis CK Yao, RE Burgell, KM Taylor, MG Ward, AB Friedman, JS Barrett, ... Journal of Gastroenterology and Hepatology 36 (6), 1580-1589, 2021 | 13 | 2021 |